Irritable bowel syndrome with diarrhea
|
phenotype |
Pathological Conditions, Signs and Symptoms; Digestive System Diseases
|
Disease or Syndrome
|
19
|
|
0.010 |
None |
1.000 |
1 |
|
2016 |
2016 |
Usher Syndrome, Type I
|
disease |
Pathological Conditions, Signs and Symptoms; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Eye Diseases; Nervous System Diseases; Otorhinolaryngologic Diseases
|
Disease or Syndrome
|
23
|
168
|
0.010 |
None |
1.000 |
1 |
|
2005 |
2005 |
Circadian Rhythms
|
phenotype |
|
Organism Function
|
45
|
84
|
0.100 |
None |
1.000 |
2 |
1
|
2016 |
2017 |
Excessive daytime sleepiness
|
phenotype |
|
Sign or Symptom
|
46
|
5
|
0.010 |
None |
1.000 |
1 |
|
2017 |
2017 |
body fat percentage (physical finding)
|
phenotype |
|
Finding
|
56
|
98
|
0.100 |
None |
1.000 |
1 |
1
|
2019 |
2019 |
Body Weight
|
phenotype |
Pathological Conditions, Signs and Symptoms
|
Organism Attribute
|
57
|
92
|
0.100 |
None |
1.000 |
1 |
1
|
2012 |
2012 |
Duration of sleep
|
phenotype |
|
Finding
|
104
|
203
|
0.100 |
None |
1.000 |
1 |
1
|
2017 |
2017 |
Organic Mental Disorders, Substance-Induced
|
disease |
Chemically-Induced Disorders; Mental Disorders
|
Mental or Behavioral Dysfunction
|
115
|
|
0.300 |
None |
1.000 |
1 |
|
2010 |
2010 |
Prescription Drug Abuse
|
phenotype |
Chemically-Induced Disorders; Mental Disorders
|
Finding
|
115
|
|
0.300 |
None |
1.000 |
1 |
|
2010 |
2010 |
Polysomnography
|
phenotype |
|
Diagnostic Procedure
|
119
|
249
|
0.100 |
None |
1.000 |
1 |
1
|
2012 |
2012 |
Drug Use Disorders
|
group |
Chemically-Induced Disorders; Mental Disorders
|
Mental or Behavioral Dysfunction
|
121
|
|
0.300 |
None |
1.000 |
1 |
|
2010 |
2010 |
Substance-Related Disorders
|
group |
Chemically-Induced Disorders; Mental Disorders
|
Mental or Behavioral Dysfunction
|
128
|
20
|
0.300 |
None |
1.000 |
1 |
|
2010 |
2010 |
Lean body mass
|
phenotype |
|
Clinical Attribute
|
144
|
211
|
0.100 |
None |
1.000 |
1 |
1
|
2012 |
2012 |
Substance Dependence
|
disease |
Chemically-Induced Disorders; Mental Disorders
|
Mental or Behavioral Dysfunction
|
156
|
19
|
0.300 |
None |
1.000 |
1 |
|
2010 |
2010 |
Substance abuse problem
|
disease |
Chemically-Induced Disorders; Mental Disorders
|
Mental or Behavioral Dysfunction
|
185
|
20
|
0.300 |
None |
1.000 |
1 |
|
2010 |
2010 |
Drug habituation
|
phenotype |
Chemically-Induced Disorders; Mental Disorders
|
Mental or Behavioral Dysfunction
|
196
|
19
|
0.300 |
None |
1.000 |
1 |
|
2010 |
2010 |
Substance Use Disorders
|
group |
Chemically-Induced Disorders; Mental Disorders
|
Mental or Behavioral Dysfunction
|
218
|
16
|
0.300 |
None |
1.000 |
1 |
|
2010 |
2010 |
Drug Dependence
|
group |
Chemically-Induced Disorders; Mental Disorders
|
Mental or Behavioral Dysfunction
|
248
|
31
|
0.300 |
None |
1.000 |
1 |
|
2010 |
2010 |
Polycystic Kidney, Autosomal Dominant
|
disease |
Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases
|
Disease or Syndrome
|
280
|
35
|
0.010 |
None |
1.000 |
1 |
|
2010 |
2010 |
Smoking
|
phenotype |
Behavior and Behavior Mechanisms
|
Individual Behavior
|
391
|
765
|
0.100 |
None |
1.000 |
1 |
1
|
2017 |
2017 |
Drug abuse
|
group |
Chemically-Induced Disorders; Mental Disorders
|
Mental or Behavioral Dysfunction
|
405
|
39
|
0.300 |
None |
1.000 |
1 |
|
2010 |
2010 |
Vital capacity
|
phenotype |
|
Clinical Attribute
|
430
|
746
|
0.100 |
None |
1.000 |
1 |
1
|
2019 |
2019 |
Adult T-Cell Lymphoma/Leukemia
|
disease |
Neoplasms; Immune System Diseases; Hemic and Lymphatic Diseases
|
Neoplastic Process
|
540
|
11
|
0.020 |
None |
1.000 |
2 |
|
2004 |
2013 |
Influenza A
|
disease |
|
Disease or Syndrome
|
563
|
19
|
0.010 |
None |
1.000 |
1 |
|
2010 |
2010 |
Waist-Hip Ratio
|
phenotype |
|
Organism Attribute
|
565
|
1138
|
0.100 |
None |
1.000 |
1 |
1
|
2019 |
2019 |